Halozyme (HALO) Eyes $21 Billion Cash Acquisition of Evotec (EVO

▤ Summary

CEO Helen Torley expressed confidence in funding the acquisition without issuing equity, relying on a combination of cash reserves and debt. The company plans to use approximately $600 million in cash on hand, supplemented by new debt financing currently being finalized with potential bank lenders. The acquisition is expected to leverage Halozymes robust cash flow to reduce debt levels swiftly post-transaction. Private equity firm Triton Partners has also shown interest in acquiring Evotec, having already disclosed holdings in the company. Torley believes this acquisition will complement Halozyme’s existing growth narrative by integrating drug discovery and production with its delivery systems.

▦ Linked Companies